About
Click our LIKE button and Share-With-A-Friend the good news and hope for a cure to mesothelioma lung cancer with Veglin!
NEWS RELEASE
November 14, 2011
Today, Dr. Parkash Gill announced that Veglin is not released yet to restart it’s Phase 2 Clinical Trials, and the project continues to wait for FDA approval. Dr. Gill is working hard to restart Veglin within Phase 2 and is also working diligently to get EPH-B4 into Phase I Clinical Trials.
Please use our FaceBook link 
to obtain your FREE copy of our eBook that teaches you 10 easy steps on how to find and choose a clinical trial for Mesothelioma and how to prepare for it!
Ask Dr. Gill about your specific mesothelioma issues here: Ask Dr. Gill
Learn more about Veglin at this cancer research link: read more…
In addition to the eBook found at our Facebook fan page, also learn more about clinical trials from these links:
The Mesothelioma Research Foundation of America has a mission: fund research that will lead to the quickest cure for mesothelioma. Mesothelioma is a cancer of the lining of the lungs caused by asbestos exposure. This cancer disease had few treatment options until this Foundation and Dr. Parkash Gill’s work created better treatment options. Today, the future looks more hopeful for additional improved treatment options available to those stricken by this cancer.
The Mesothelioma Research Foundation of America began funding research for a cure in 2001 with the opening of the Mesothelioma Laboratory at USC Norris Comprehensive Cancer Medical Center in Los Angeles under the supervision of Dr. Parkash Gill.
Clinical trials of Veglin
Dr. Gill is a board certified oncologist and hematologist who has received FDA approval from the U.S. Government to do Clinical Trials on a mesothelioma treatment drug called Veglin. We believe there is great promise and hope in Veglin and the Mesothelioma Research Foundation of America has funded 100% of Dr. Gill’s research.
Veglin proved successful in Phase I and Phase II clinical trials. Many are very hopeful for the possibilities of a more effective cancer treatment compared to what presently is available for mesothelioma victims.